Home » Authors » Trista Morrison

Articles by Trista Morrison

Ex-Cabrellis Team Launches Tragara With $40M Series A

March 15, 2007

By Trista Morrison

Ex-Cabrellis Team Launches Tragara With $40M Series A

March 15, 2007

By Trista Morrison

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

March 14, 2007

By Trista Morrison

A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

March 14, 2007

By Trista Morrison

A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)

Takeda Deal With Paradigm Expands To Acquisition

March 13, 2007

By Trista Morrison

Takeda Deal With Paradigm Expands To Acquisition

March 13, 2007

By Trista Morrison

Conference Recaps Trends, Challenges and Opportunities

March 9, 2007

By Trista Morrison

Hollis-Eden Down On HHS Rejection of Radiation Drug

March 9, 2007

By Trista Morrison

Hollis-Eden Down On HHS Rejection of Radiation Drug

March 9, 2007

By Trista Morrison

Conference Recaps Trends, Challenges and Opportunities

March 9, 2007

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...